ENTPD1 and head and neck squamous cell carcinoma: As reported in previous HNSCC clinical trials26, we observed an increase in CD103+CD39+ CD8+ T cells in responders both pre- and post-treatment, and increased Ki-67 and TCF1 expression, in this cell population, post-treatment (Fig. 2c).